Altimmune Inc
NASDAQ: ALT
$8.41
+$0.36 (+4.4%)
Closing Price on November 21, 2024
ALT Stock Chart and Intraday Price
ALT Stock Data
| Asset Type | Stock |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | LIFE SCIENCES |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Address | 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG, MD, US |
| Fiscal Year End | December |
| Latest Quarter | 9/30/2023 |
| Market Cap | 649.58M USD |
| Shares Outstanding | 53,729,000 |
ALT Articles
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX), for example. Now trading at $57.80, we strongly believe it could easily rally...
Published:
Thursday’s additional top analyst upgrades and downgrades were on Ally Financial, Altimmune, Capital One Financial, GoodRx, Leslie’s, PagSeguro Digital, Regions Financial, Sirius XM, StoneCo,...
Published:
Wednesday afternoon's top analyst upgrades and downgrades included Inovio Pharmaceuticals, McDonald’s, Orchard Therapeutics, VBI Vaccines and Wingstop.
Published:
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
Published:
Wednesday's top analyst upgrades and downgrades included Alphabet, Canopy Growth, Cinemark, Dick's Sporting Goods, Facebook, IMAX, Microsoft, Salesforce.com and SBA Communications.
Published:
Altimmune has announced additional preclinical data in regards to its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
Published:
Thursday's top analyst upgrades and downgrades included Allstate, Bed Bath & Beyond, Simon Property, Spirit Airlines, Twitter and Under Armour.
Published:
Altimmune shares dropped on Thursday after the company announced that it had received an update from the FDA regarding its COVID-19 vaccine candidate.
Published:
Altimmune made a step forward on Tuesday with its vaccine candidate for COVID-19. Specifically, the firm entered into a manufacturing agreement the vaccine candidate.
Published:
Last Updated:
Altimmune made some progress with its COVID-19 treatment on Monday after it announced some new funding for its trials.
Published:
Last Updated:
24/7 Wall St. has tracked some stocks that either are defensive in general or are defying Monday's big drop because they have some aspect of their business that might be immune to daily scares or...
Published:
Altimmune shares surged on Tuesday following results from its midstage study of a intranasal influenza vaccine candidate.
Published:
Last Updated: